Adage Capital Partners
EPZM

Adage Capital Partners’s Epizyme, Inc EPZM Stock Holding History

Adage Capital Partners’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-403,000
Closed -$7.15M – 808
2018
Q1 		$7.15M Buy
+403,000
New +$6.81M 0.02% 605
2014
Q4 		– Sell
-100,000
Closed -$2.71M – 777
2014
Q3 		$2.71M Buy
+100,000
New +$3.11M 0.01% 660
2013
Q4 		– Sell
-313,380
Closed -$12.5M – 734
2013
Q3 		$12.5M Sell
313,380
-11,620
-4% -$394K 0.04% 462
2013
Q2 		$9.14M Buy
+325,000
New +$8.35M 0.03% 516

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners's EPZM Position: Q2 2018 in Review

Adage Capital Partners sold out of Epizyme, Inc (EPZM) in Q2 2018, closing a stake of 403,000 shares — an estimated $7.15M sold.

Adage Capital Partners first reported a position in EPZM in Q2 2013 and held it in 4 quarters. The position peaked at $12.5M in Q3 2013. 109 funds tracked by Wall St. Rank hold EPZM as of Q2 2018.

  • Adage Capital Partners reported no remaining Epizyme, Inc position as of Q2 2018 after selling out during the quarter.
  • Adage Capital Partners sold 403,000 Epizyme, Inc shares in Q2 2018, an estimated $7.15M.
  • Adage Capital Partners first reported a position in Epizyme, Inc in Q2 2013 and held it in 4 quarters.
  • Adage Capital Partners's Epizyme, Inc position peaked at $12.5M in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2018.

Based on Adage Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.